---
title: "KPV"
slug: "kpv"
type: "compound"
category: "Recovery"
url: "https://peptidesciencethailand.com/compounds/kpv"
description: "A tripeptide fragment of alpha-MSH that inhibits NF-kB signaling and shows promise in gut inflammation research. Anti-inflammatory mechanism and evidence."
---
# KPV

*Alpha-MSH Derived Tripeptide, Modulating Inflammatory Cascades at the Cellular Level*

**Category:** Recovery  
**Format:** Lyophilized Vial  
**Amount:** 5mg  
**Purity:** >99% (HPLC)

## Overview

KPV is a naturally occurring tripeptide consisting of the amino acid sequence Lys-Pro-Val (lysine-proline-valine), corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). With a molecular weight of 342.43 g/mol and the molecular formula C16H30N4O4, KPV represents the minimal bioactive sequence responsible for the potent anti-inflammatory activity of the full alpha-MSH molecule. First identified through structure-activity relationship studies of alpha-MSH fragments, KPV was found to retain the anti-inflammatory properties of the parent hormone while lacking its melanogenic (skin-darkening) and melanocortin receptor-dependent hormonal effects.

The discovery of KPV's anti-inflammatory properties emerged from research into the immunomodulatory functions of melanocortin peptides. Alpha-MSH, a 13-amino acid peptide produced by post-translational processing of proopiomelanocortin (POMC), has long been recognized as a potent endogenous anti-inflammatory mediator. However, its activity at melanocortin receptors (particularly MC1R through MC5R) produces hormonal effects including melanogenesis, appetite suppression, and sexual function modulation that limit its therapeutic selectivity. KPV, as the C-terminal tripeptide (residues 11-13), was found to mediate anti-inflammatory activity through a melanocortin receptor-independent mechanism, providing selective anti-inflammatory action without the broader hormonal effects of full-length alpha-MSH.

The primary anti-inflammatory mechanism of KPV involves direct inhibition of the nuclear factor kappa B (NF-kB) signaling pathway, the master transcriptional regulator of inflammatory gene expression. NF-kB controls the expression of over 400 genes involved in inflammation, immunity, and cell survival, including pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IL-8), chemokines, adhesion molecules, and inducible enzymes (COX-2, iNOS). Under inflammatory conditions, NF-kB is activated through phosphorylation and degradation of its cytoplasmic inhibitor IkB-alpha, allowing NF-kB dimers to translocate to the nucleus and activate target gene transcription.

KPV inhibits this process at multiple points. Research has demonstrated that KPV enters cells and directly interacts with the IKK complex (IkB kinase), the upstream kinase responsible for IkB-alpha phosphorylation. By inhibiting IKK activity, KPV prevents IkB-alpha degradation and maintains NF-kB in its inactive cytoplasmic state, effectively blocking the entire downstream inflammatory transcriptional program. Studies published in the Journal of Biological Chemistry have shown that KPV reduces NF-kB nuclear translocation by up to 70% in stimulated inflammatory cells, producing a broad suppression of pro-inflammatory mediator production.

Beyond NF-kB inhibition, KPV modulates inflammatory signaling through interaction with the JAK-STAT pathway, another critical mediator of immune cell activation and cytokine signaling. KPV has been shown to reduce phosphorylation of STAT3, a transcription factor activated by inflammatory cytokines that drives the expression of acute-phase proteins and perpetuates inflammatory cascades. This dual inhibition of both NF-kB and JAK-STAT pathways produces a comprehensive anti-inflammatory effect that targets multiple nodes of the inflammatory network simultaneously.

The gastrointestinal research applications of KPV have attracted considerable scientific interest. The gut mucosa is a major site of inflammatory regulation, and dysregulated intestinal inflammation contributes to conditions including inflammatory bowel disease, colitis, and intestinal permeability. Research published in the journal Inflammatory Bowel Diseases demonstrated that KPV significantly reduced colonic inflammation in animal models of experimental colitis. Oral administration of KPV reduced histological damage scores, decreased mucosal TNF-alpha and IL-6 levels, preserved epithelial barrier integrity, and reduced neutrophil infiltration into inflamed tissue. Importantly, these effects were observed with oral dosing, indicating that KPV retains biological activity in the gastrointestinal tract despite the proteolytic environment of the gut lumen.

The mechanism by which KPV exerts its intestinal anti-inflammatory effects involves direct interaction with colonic epithelial cells and lamina propria immune cells. Research has shown that KPV is taken up by intestinal epithelial cells via the PepT1 transporter, a proton-coupled oligopeptide transporter expressed on the apical membrane of enterocytes. Once internalized, KPV inhibits NF-kB activation within epithelial cells, reducing their production of inflammatory chemokines that recruit immune cells to the mucosa. Simultaneously, KPV acts on lamina propria macrophages and dendritic cells, shifting their polarization from pro-inflammatory (M1/DC1) toward tolerogenic (M2/DC2) phenotypes.

KPV also demonstrates antimicrobial properties that complement its anti-inflammatory activity. Research has shown that KPV exhibits direct antimicrobial activity against several bacterial species, including Staphylococcus aureus, Candida albicans, and Escherichia coli. This antimicrobial action is mediated through disruption of bacterial membrane integrity and inhibition of bacterial biofilm formation. The combination of anti-inflammatory and antimicrobial properties is particularly relevant for gastrointestinal research, where microbial dysbiosis and mucosal inflammation are often interconnected.

The wound healing properties of KPV have been documented in preclinical studies examining skin and mucosal repair. KPV promotes wound closure through stimulation of epithelial cell migration and proliferation, effects that are independent of its anti-inflammatory activity. Research has demonstrated that KPV increases the expression of transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) in wound-edge keratinocytes, activating the cellular migration programs necessary for re-epithelialization. These wound healing effects, combined with the anti-inflammatory and antimicrobial properties, position KPV as a multi-functional peptide for tissue repair research.

Pharmacokinetically, KPV offers advantages over full-length alpha-MSH due to its smaller size and resistance to aminopeptidase degradation. While alpha-MSH is rapidly cleaved by serum aminopeptidases, the N-terminal lysine of KPV provides relative resistance to this degradation, extending its effective half-life. The tripeptide is also more amenable to oral delivery than larger peptides, as demonstrated by its intestinal uptake via PepT1 and its biological activity following oral administration in colitis models. These pharmacokinetic properties make KPV a practical research compound for both systemic and local applications.

## Mechanism of Action

### Step 1: Cellular Uptake and IKK Complex Interaction

KPV enters target cells (including intestinal epithelial cells via the PepT1 transporter) and directly interacts with the IKK complex (IkB kinase), the upstream activating kinase of the NF-kB inflammatory signaling pathway.

### Step 2: NF-kB Pathway Inhibition

By inhibiting IKK activity, KPV prevents phosphorylation and degradation of IkB-alpha, maintaining NF-kB in its inactive cytoplasmic state. This blocks nuclear translocation by up to 70%, suppressing transcription of over 400 pro-inflammatory genes.

### Step 3: JAK-STAT Pathway Modulation

KPV concurrently reduces STAT3 phosphorylation, inhibiting the JAK-STAT signaling cascade that amplifies inflammatory cytokine signaling. This dual-pathway inhibition produces comprehensive anti-inflammatory coverage.

### Step 4: Immune Cell Polarization Shift

KPV promotes the polarization of macrophages from pro-inflammatory M1 toward anti-inflammatory M2 phenotypes, and similarly shifts dendritic cells toward tolerogenic DC2 profiles, reducing tissue-level inflammatory cell activation.

### Step 5: Mucosal Repair and Barrier Restoration

Downstream effects include reduced mucosal cytokine levels, preserved epithelial barrier integrity, enhanced wound healing through TGF-beta and EGFR upregulation, and direct antimicrobial activity against pathogenic bacteria and biofilms.

## Researched Benefits

### Potent Anti-Inflammatory Activity

KPV inhibits the NF-kB pathway at the IKK level, producing broad suppression of pro-inflammatory gene expression. Research demonstrates up to 70% reduction in NF-kB nuclear translocation, leading to decreased production of TNF-alpha, IL-1beta, IL-6, and other inflammatory mediators without the immunosuppressive effects of corticosteroids.

### Gastrointestinal Mucosal Protection

Preclinical studies in colitis models show that oral KPV reduces histological damage, decreases mucosal cytokine levels, preserves epithelial barrier integrity, and reduces neutrophil infiltration. Its uptake by intestinal epithelial cells via the PepT1 transporter enables direct local anti-inflammatory action in the gut mucosa.

### Selective Anti-Inflammatory Action

Unlike full-length alpha-MSH, KPV mediates its anti-inflammatory effects through a melanocortin receptor-independent mechanism. This provides selective inflammation modulation without melanogenic (skin-darkening), appetite-suppressive, or other hormonal effects associated with melanocortin receptor activation.

### Antimicrobial and Wound Healing Properties

KPV exhibits direct antimicrobial activity against Staphylococcus aureus, Candida albicans, and E. coli through membrane disruption and biofilm inhibition. It simultaneously promotes wound healing through TGF-beta and EGFR-mediated epithelial cell migration, providing multi-functional tissue repair support.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 200-500mcg per day, administered subcutaneously or orally |
| Route | Subcutaneous injection or oral administration |
| Duration | 4-8 weeks per cycle |
| Cycle Notes | Research protocols vary based on the target application. For gut-focused protocols, oral administration is preferred to deliver KPV directly to the intestinal epithelium via PepT1-mediated uptake. For systemic anti-inflammatory applications, subcutaneous injection provides more predictable systemic bioavailability. |
| Reconstitution | Reconstitute lyophilized KPV with bacteriostatic water. A 5mg vial reconstituted with 2mL yields 2500mcg/mL concentration. Store reconstituted solution at 2-8°C and use within 28 days. |

> **Specialist note:** A your specialist will evaluate the specific inflammatory condition, concurrent medications (particularly immunomodulators, corticosteroids, or biologics), and overall immune status before initiating a KPV protocol. While KPV's anti-inflammatory mechanism is selective, individuals with compromised immune function or active infections require careful assessment.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Lyophilized Powder |
| Amount | 5mg per vial |
| Purity | >99% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Sequence | Lys-Pro-Val (C-terminal tripeptide of alpha-MSH, residues 11-13) |
| Molecular Weight | 342.43 g/mol |
| Storage | Store lyophilized powder at -20°C. Reconstituted solution at 2-8°C. Protect from light. |
| Appearance | White to off-white lyophilized powder |

## Medical Guidance

KPV modulates core inflammatory signaling pathways (NF-kB and JAK-STAT) that are also targeted by prescription anti-inflammatory and immunomodulatory medications. Individuals taking corticosteroids, TNF-alpha inhibitors, JAK inhibitors, or other immunomodulatory drugs require specialist assessment to evaluate potential additive immunosuppressive effects. Those with active infections, immunodeficiency states, or autoimmune conditions on treatment require careful evaluation of the risk-benefit balance of additional inflammatory pathway modulation.

## Frequently Asked Questions

### What is KPV and where does it come from?

KPV is a naturally occurring tripeptide with the sequence Lys-Pro-Val (lysine-proline-valine). It corresponds to the C-terminal three amino acids (positions 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH), an endogenous immunomodulatory peptide derived from proopiomelanocortin (POMC). KPV retains the anti-inflammatory properties of full-length alpha-MSH while lacking its melanogenic and hormonal effects.

### How does KPV differ from alpha-MSH?

Alpha-MSH is a 13-amino acid peptide that acts through melanocortin receptors (MC1R-MC5R) to produce effects including melanogenesis (skin darkening), appetite suppression, and anti-inflammation. KPV, as the minimal anti-inflammatory fragment, mediates its effects through a melanocortin receptor-independent mechanism (direct NF-kB and JAK-STAT inhibition), providing selective anti-inflammatory action without hormonal side effects.

### Can KPV be taken orally for gut-related applications?

Yes. Research has demonstrated that KPV retains biological activity when administered orally. The tripeptide is taken up by intestinal epithelial cells via the PepT1 oligopeptide transporter, enabling direct delivery to the gut mucosa. Animal studies of experimental colitis showed significant reductions in intestinal inflammation with oral KPV administration, including reduced histological damage and mucosal cytokine levels.

### Does KPV cause skin darkening like other melanocortin peptides?

No. KPV does not cause melanogenesis (skin darkening). Full-length alpha-MSH and peptides like Melanotan-2 stimulate melanin production by activating MC1R on melanocytes. KPV's anti-inflammatory mechanism is melanocortin receptor-independent, meaning it does not activate MC1R and does not produce tanning or pigmentation changes.

### What research supports KPV for inflammatory conditions?

Preclinical studies published in Inflammatory Bowel Diseases, the Journal of Biological Chemistry, and other peer-reviewed journals have demonstrated KPV's anti-inflammatory efficacy in models of colitis, skin inflammation, and wound healing. Key findings include up to 70% reduction in NF-kB activation, significant decreases in pro-inflammatory cytokines, preserved epithelial barrier function, and direct antimicrobial activity. Human clinical data are limited, and ongoing research continues to characterize the compound's therapeutic potential.

## Related Compounds

- /compounds/bpc-157
- /compounds/tb-500
- /compounds/ll-37